Goiter rate, serum thyrotropin, thyroid autoantibodies and urinary iodine concentration in Tehranian adults before and after national salt iodization

Journal of Endocrinological Investigation

Volumn 30, Issue 5, 2007, Pages 404-410

  Heydarian, P ^a   Ordookhani, A ^b   Azizi, F ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Goiter; Smoking; Thyroid autoantibodies; Thyroid hormones; Thyrotropin; Urinary iodine

Indexed keywords

IODINE; SODIUM CHLORIDE; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; AUTOANTIBODY; IODIZED SALT; UNCLASSIFIED DRUG;

ADULT; AGGLUTINATION TEST; ARTICLE; DIET SUPPLEMENTATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; GOITER; HEALTH PROGRAM; HUMAN; HUMAN EXPERIMENT; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINATION; IRAN; MALE; MEN'S HEALTH; PREVALENCE; STATISTICAL SIGNIFICANCE; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; URINE LEVEL; AGE DISTRIBUTION; BLOOD; ENDEMIC GOITER; EPIDEMIOLOGY; FACTUAL DATABASE; HEALTH CARE POLICY; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; SALT INTAKE; SMOKING; THYROID GLAND; URINE;

ADULT; AGE DISTRIBUTION; AUTOANTIBODIES; DATABASES, FACTUAL; FEMALE; GOITER, ENDEMIC; HEALTH POLICY; HUMANS; IODINE; IRAN; MALE; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SMOKING; SODIUM CHLORIDE, DIETARY; THYROID GLAND; THYROTROPIN;

EID: 34447636940     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346318     Document Type: Article

References (25)

1. Emami A, Shahbazi H, Sabzevari M, et al. Goiter in Iran. Am J Clin Nutr 1969, 22: 1584-8.
2. Azizi F, Kimiagar M, Nafarabadi M, Yassai M. Current status of iodine deficiency in the Islamic Republic of Iran. EMR Health Serv J 1990, 8: 23-7.
3. Azizi F, Sheikholeslam R, Mirmiran P. IDD Newsletter 2006 (in press)
4. Azizi F, Sheikholeslam R, Hedayati M, et al. Sustainable control of iodine deficiency in Iran: beneficial results of the implementation of the mandatory law on salt iodization. J Endocrinol Invest 2002, 25: 409-13.
5. Azizi F, Rahmani M, Emami H, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 2002, 47: 408-26.
6. Sandell EB, Kolthoff IM. Micro-determination of iodine by a catalytic method. Mikrochimica Acta 1937, 1: 9-25.
7. Hetzel BS. Eliminating iodine deficiency disorders-the role of the International Council in the global partnership. Bull World Health Org 2002, 80: 410-3.
8. Delange F. Iodine deficiency as a cause of brain damage. Postgrad Med J 2001, 77: 217-20.
9. Delange F, cle Benoist B, Pretell E, Dunn JT. Iodine deficiency in the world: where do we stand at the turn of the century?. Thyroid 2001, 11: 437-47.
10. Vitti P, Delange F, Pinchera A, Zimmermann M, Dunn JT Europe is iodine deficient. Lancet 2003, 361: 1226.
11. WHO/UNICEF/ICCIDD. Assessment of the iodine deficiency disorders and monitoring their elimination. Geneva: World Health Organization. 2001, Publication WHO/NHD/01.1: 1-107.
12. Delange F. Risks and benefits of iodine supplementation. Lancet 1998, 351: 923-4.
13. Kahaly GJ, Dienes HP, Beyer J, Hommel G. Iodide induces thyroid autoimmunity in patients with endemic goiter: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol 1998, 139: 290-7.
14. Zois C, Stavrou I, Kalogera C, et al. High prevalence of autoimmune thyroiditis in school children after elimination of iodine deficiency in northwestern Greece. Thyroid 2003, 13: 485-9.
15. Markou KB, Georgopoulos NA, Makri M, et al. Improvement of iodine deficiency after iodine supplementation in schoolchildren of Azerbaijan was accompanied by hypo and hyperthyrotropinemia and increased title of thyroid autoantibodies. J Endocrino Invest 2003, 26 (2 Suppl): 43-8.
16. Doufas AG, Mastorakos G, Chatziioannou S, et al. The predominant form of non-toxic goiter in Greece is now autoimmune thyroiditis. Eur J Endocrinol 1999, 140: 505-11.
17. Azizi F, Hedayati M, Rahmani M, Sheikholeslam R, Allahverdian S, Salarkia N. Reappraisal of the risk of iodine-induced hyperthyroidism: anepidemiological population survey. J Endocrinol Invest 2005, 28: 23-9.
18. Wartofsky L, Dickey RA. Controversy in clinical endocrinology: the evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 2005, 90: 5483-8.
19. Surks MI, Goswami G, Daniels GH. Controversy in clinical endocrinology: the thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab 2005, 90: 5489-96.
20. O'Leary PC, Feddema PH, Michelangeli VP, et al. Investigations of hormones and antibodies based on a community health survey: the Busselton thyroid study. Clin Endocrinol (Oxf) 2006, 64: 97-104.
21. Khaleeli AA. Prevalence of thyroid antibodies in Shiraz, Iran, an area with iodine deficiency. Postgrad Med J 1981, 57: 23-7.
22. Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004, 89: 6077-86.
23. Strieder TGA, Prummel MF, Tijssen JGP, Endert E, Wiersinga WM. Risk factors and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003, 59: 396-401.
24. Harrison B. Influence of cigarette smoking on disease outcome in rheumatoid arthritis. Curr Opin Rheumatol 2002, 14: 93-7.
25. Jeremy J, Mikhailidis D. Vascular and platelet eicosanoids, smoking and atherosclerosis. Adv Exp, Med Biol 1990, 273: 135-46.